Hemispherx Biopharma Inc. Announces Updated Information about ME/CFS Expanded Access Program in the United States
December 17, 2018 08:30 ET
|
Hemispherx Biopharma, Inc.
OCALA, Fla., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in...
Hemispherx Biopharma Issues Letter to Stockholders
December 12, 2018 08:30 ET
|
Hemispherx Biopharma, Inc.
OCALA, Fla., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) announces that Thomas K. Equels, President and Chief Executive Officer, has issued a Letter to...
Hemispherx Reports 2018 Third Quarter and First Nine Months Financial Results
November 15, 2018 09:04 ET
|
Hemispherx Biopharma, Inc.
OCALA, Fla., Nov. 15, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) announces financial results for the three and nine months ended September 30, 2018, and provides a...
Hemispherx’s Presentation at the Dawson James Securities 4th Annual Small Cap Growth Conference to Be Livestreamed
October 29, 2018 18:39 ET
|
Hemispherx Biopharma, Inc.
OCALA, Fla., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in...
Hemispherx to Present at the Dawson James Securities 4th Annual Small Cap Growth Conference
October 24, 2018 08:30 ET
|
Hemispherx Biopharma, Inc.
ORLANDO, Fla., Oct. 24, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in...
Hemispherx Outlines Ampligen Combination Therapy Clinical Study Strategy for the Treatment of Multiple Cancers in Letter to Stockholders
October 22, 2018 08:30 ET
|
Hemispherx Biopharma, Inc.
ORLANDO, Fla., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) announces that Thomas K. Equels, President and Chief Executive Officer, has issued a Letter to...
Hemispherx Biopharma Signs Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center to Study Ampligen in Combination with Checkpoint Inhibitors in a Phase IIa Study in Urothelial Carcinoma, Renal Cell Carcinoma and Melanoma
October 10, 2018 08:30 ET
|
Hemispherx Biopharma, Inc.
OCALA, Fla., Oct. 10, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) announces the signing of a clinical trial agreement with Roswell Park Comprehensive Cancer Center to...
Hemispherx to Distribute Second Lot of Ampligen® for use in Multiple Indications in Argentina, the United States and Europe
September 18, 2018 08:30 ET
|
Hemispherx Biopharma, Inc.
ORLANDO, Fla., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) announced today regulatory inspection and clearance for distribution of the Company’s second...
Hemispherx Releases Recently Manufactured Ampligen for Pancreatic Cancer Early Access Program in the Netherlands to Fill Stock Order
August 28, 2018 08:30 ET
|
Hemispherx Biopharma, Inc.
ORLANDO, Fla., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) announced today that the new Ampligen batch manufactured earlier this year is now released for...
Hemispherx to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
August 24, 2018 08:30 ET
|
Hemispherx Biopharma, Inc.
ORLANDO, Fla., Aug. 24, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in...